Literature DB >> 2276387

N-acetylation in healthy and diseased children.

E Hadasová1, V Brysová, E Kadlcáková.   

Abstract

Acetylation capacity was examined in three groups of Czech children by measuring the plasma and urine concentrations of sulphamethazine and its acetylated metabolite 6 h after an oral test dose of 20 mg/kg sulphamethazine. Amongst 82 healthy children aged 4-15 y there were 32 (39%) fast acetylators; there was no significant difference between the number of boys and girls, or between children over or less than 6 years of age. In 41 patients aged 3-15 y with phenylketonuria, the acetylation indices showed a significantly higher proportion of fast acetylators - 24 (58.5%) using plasma measurements and 29 (70.7%) using urine data. In them the ratio between slow and fast acetylators was inverted compared to normal children. The preponderance of fast acetylators was greater in boys than in girls and in children over 6 years of age. An increased acetylation capacity in patients with phenylketonuria was apparent even in individuals classified as slow acetylators, because in them the plasma concentration of the acetylated metabolite was higher than in control acetylators. Amongst 48 young patients (5-15 y) with insulin-dependent diabetes there were 19 (39.6%) fast and 29 (60.4%) slow acetylators, which corresponded well to the phenotype distribution in control children. This did not support the suggested association between the fast acetylator phenotype and Type I diabetes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276387     DOI: 10.1007/bf02657055

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  Hepatic drug acetylation and oxidation: effects of aging in man.

Authors:  F Farah; W Taylor; M D Rawlins; O James
Journal:  Br Med J       Date:  1977-07-16

2.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

3.  Distribution of acetylator phenotype in relation to age and sex in Swedish patients. A retrospective study.

Authors:  O Paulsen; L G Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  [Therapeutic consequences of measure of inactivation index of isoniazid during antituberculous therapy (author's transl)].

Authors:  G Houin; J P Tillement
Journal:  Therapie       Date:  1980 Sep-Oct       Impact factor: 2.070

5.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

6.  Hepatic acetylator phenotype in diabetes mellitus.

Authors:  J M Ladero; A Arrojo; R E de Salamanca; M Gomez; F Cano; M Alfonso
Journal:  Ann Clin Res       Date:  1982-08

7.  The association of the slow acetylator phenotype with bladder cancer.

Authors:  D A Evans; L C Eze; E J Whibley
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

8.  The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients.

Authors:  M J Mattila; H Tiitinen
Journal:  Ann Med Exp Biol Fenn       Date:  1967

9.  Acetylator status and diabetic neuropathy.

Authors:  G M Shenfield; V J McCann; R Tjokresetio
Journal:  Diabetologia       Date:  1982-06       Impact factor: 10.122

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more
  3 in total

1.  Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.

Authors:  Joshua E Muscat; Brian Pittman; Wayne Kleinman; Philip Lazarus; Steven D Stellman; John P Richie
Journal:  Biochem Pharmacol       Date:  2008-07-25       Impact factor: 5.858

2.  Acetylator phenotypes of Jordanian diabetics.

Authors:  Y Irshaid; H al-Hadidi; M Abuirjeie; A Latif; O Sartawi; N Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Authors:  Catherine Ganiere-Monteil; Yves Medard; Corinne Lejus; Béatrice Bruneau; Alain Pineau; Odile Fenneteau; Michel Bourin; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.